Search

Purpose To determine whether the unsupervised domain adaptation (UDA) method with generated images improves the performance of a supervised learning (SL) model for prostate cancer (PCa) detection using multisite biparametric (bp) MRI datasets. Materials and Methods This retrospective study included data from 5150 patients (14 191 samples) collected across nine different imaging centers. A novel UDA method using a unified generative model was developed for PCa detection using multisite bpMRI datasets. This method translates diffusion-weighted imaging (DWI) acquisitions, including apparent diffusion coefficient (ADC) and individual diffusion-weighted (DW) images acquired using various b values, to align with the style of images acquired using b values recommended by Prostate Imaging Reporting and Data System (PI-RADS) guidelines. The generated ADC and DW images replace the original images for PCa detection. An independent set of 1692 test cases (2393 samples) was used for evaluation. The area under the receiver operating characteristic curve (AUC) was used as the primary metric, and statistical analysis was performed via bootstrapping. Results For all test cases, the AUC values for baseline SL and UDA methods were 0.73 and 0.79 ( P < .001), respectively, for PCa lesions with PI-RADS score of 3 or greater and 0.77 and 0.80 ( P < .001) for lesions with PI-RADS scores of 4 or greater. In the 361 test cases under the most unfavorable image acquisition setting, the AUC values for baseline SL and UDA were 0.49 and 0.76 ( P < .001) for lesions with PI-RADS scores of 3 or greater and 0.50 and 0.77 ( P < .001) for lesions with PI-RADS scores of 4 or greater. Conclusion UDA with generated images improved the performance of SL methods in PCa lesion detection across multisite datasets with various b values, especially for images acquired with significant deviations from the PI-RADS-recommended DWI protocol (eg, with an extremely high b value). Keywords: Prostate Cancer Detection, Multisite, Unsupervised Domain Adaptation, Diffusion-weighted Imaging, b Value Supplemental material is available for this article. © RSNA, 2024.

Background: Deep-learning-based computer-aided diagnosis (DL-CAD) systems using MRI for prostate cancer (PCa) detection have demonstrated good performance. Nevertheless, DL-CAD systems are vulnerable to high heterogeneities in DWI, which can interfere with DL-CAD assessments and impair performance. This study aims to compare PCa detection of DL-CAD between zoomed-field-of-view echo-planar DWI (z-DWI) and full-field-of-view DWI (f-DWI) and find the risk factors affecting DL-CAD diagnostic efficiency., Methods: This retrospective study enrolled 354 consecutive participants who underwent MRI including T2WI, f-DWI, and z-DWI because of clinically suspected PCa. A DL-CAD was used to compare the performance of f-DWI and z-DWI both on a patient level and lesion level. We used the area under the curve (AUC) of receiver operating characteristics analysis and alternative free-response receiver operating characteristics analysis to compare the performances of DL-CAD using f- DWI and z-DWI. The risk factors affecting the DL-CAD were analyzed using logistic regression analyses. P values less than 0.05 were considered statistically significant., Results: DL-CAD with z-DWI had a significantly better overall accuracy than that with f-DWI both on patient level and lesion level (AUC patient : 0.89 vs. 0.86; AUC lesion : 0.86 vs. 0.76; P < .001). The contrast-to-noise ratio (CNR) of lesions in DWI was an independent risk factor of false positives (odds ratio [OR] = 1.12; P < .001). Rectal susceptibility artifacts, lesion diameter, and apparent diffusion coefficients (ADC) were independent risk factors of both false positives (OR rectal susceptibility artifact  = 5.46; OR diameter, = 1.12; OR ADC  = 0.998; all P < .001) and false negatives (OR rectal susceptibility artifact  = 3.31; OR diameter  = 0.82; OR ADC  = 1.007; all P ≤ .03) of DL-CAD., Conclusions: Z-DWI has potential to improve the detection performance of a prostate MRI based DL-CAD., Trial Registration: ChiCTR, NO. ChiCTR2100041834 . Registered 7 January 2021., (© 2023. The Author(s).)